| Name | Eden Research |
|---|---|
| Epic | EDEN |
| Isin | GB0001646941 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 3.80p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £20.27 | Debt ratio | n/a |
| Shares in issue | 533.35 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -76.53 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -1.54 | 52-week high / low | 3.50p / 6.10p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Eden Research |
|---|---|
| Address | 67C Innovation Drive, Milton Park, Abingdon, Oxfordshire, England, United Kingdom, OX14 4RQ |
| Telephone | |
| Website | http://www.edenresearch.com/ |
| Director | Position |
|---|---|
| Mr Sean M. Smith | CEO |
| Mr Alexander John Abrey | CFO |
| Mr Robin James Scott Cridland | Non-Executive Director |
| Mr Derek McAllan | Non-Executive Director |
| Mr Lykele van der Broek | Non-Executive Chairman |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 4.71 | 8.45 | 7.92 |
| Investments and other non-current assets | n/a | n/a | 0.36 |
| Total non-current assets | 5.45 | 9.31 | 8.89 |
| Inventory / work in progress | 0.96 | 0.62 | 0.52 |
| Trade and other receivables | 2.45 | 0.66 | 0.89 |
| Cash and equivalents | 7.41 | 1.99 | 3.83 |
| Other current assets and asset held for resale | 0.32 | 0.32 | 0.9 |
| Total of all assets | 16.59 | 12.91 | 15.03 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 2.96 | 1.95 | 1.81 |
| Long term liabilities | 0.09 | 0.22 | 0.39 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 3.05 | 2.17 | 2.2 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 13.55 | 10.74 | 12.83 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 5.33 | 3.81 | 3.8 |
| Minority interests | 0.03 | 0.03 | n/a |
| Retained earnings | 1.01 | -43.31 | -41.41 |
| Share premium account | 6.41 | 39.31 | 39.31 |
| Total equity | 13.55 | 10.74 | 12.83 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -1.87 | -2.57 | -3.21 |
| Pre-tax profit | -6.92 | -2.57 | -3.4 |